Advertisement

Pulmonary Evaluation of Liver Transplant Candidates

  • Hilary M. DuBrockEmail author
  • Michael J. Krowka
Chapter

Abstract

Pulmonary conditions, such as chronic obstructive pulmonary disease, interstitial lung disease, hepatic hydrothorax, hepatopulmonary syndrome (HPS), and portopulmonary hypertension (POPH), commonly affect liver transplant (LT) candidates. A systematic preoperative pulmonary evaluation and a basic understanding of these conditions are necessary in order to recognize and manage these comorbid diseases. Pulmonary vascular complications of liver disease, such as HPS and POPH, can affect mortality as well as LT eligibility and prioritization. This chapter will provide an overview of the pulmonary evaluation of LT candidates with an emphasis on the perioperative evaluation and management of the pulmonary vascular complications of liver disease, i.e., HPS and POPH.

Keywords

Portopulmonary hypertension Hepatopulmonary syndrome Pulmonary evaluation 

References

  1. 1.
    Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA, Sitbon O, Sokol RJ. International liver transplant society practice guidelines: diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016;100:1440–52.CrossRefGoogle Scholar
  2. 2.
    Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, Shah VH, Kaplowitz N, Forman L, Wille K, Kawut SM. Pulmonary vascular complications of liver disease study G. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology. 2008;135:1168–75.CrossRefGoogle Scholar
  3. 3.
    Roberts KE, Kawut SM, Krowka MJ, Brown RS Jr, Trotter JF, Shah V, Peter I, Tighiouart H, Mitra N, Handorf E, Knowles JA, Zacks S, Fallon MB. Pulmonary vascular complications of liver disease study G. Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology. 2010;139:130–9. e124CrossRefGoogle Scholar
  4. 4.
    Savale L, Sattler C, Coilly A, Conti F, Renard S, Francoz C, Bouvaist H, Feray C, Borentain P, Jais X, Montani D, Parent F, O'Connell C, Herve P, Humbert M, Simonneau G, Samuel D, Calmus Y, Duvoux C, Durand F, Duclos-Vallee JC, Sitbon O. Long-term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology. 2017;65:1683–92.CrossRefGoogle Scholar
  5. 5.
    Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology. 2006;44:1502–10.CrossRefGoogle Scholar
  6. 6.
    Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, Bernuau J, Marty J, Lebrec D, Valla D, Durand F. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401–9.CrossRefGoogle Scholar
  7. 7.
    Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Brown RS Jr, Fallon MB. Pulmonary vascular complications of liver disease study G. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48:196–203.CrossRefGoogle Scholar
  8. 8.
    Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Kawut SM. Pulmonary vascular complications of liver disease study G. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835–42.CrossRefGoogle Scholar
  9. 9.
    Talwalkar JA, Swanson KL, Krowka MJ, Andrews JC, Kamath PS. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology. 2011;141:1673–9.CrossRefGoogle Scholar
  10. 10.
    DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, Curry MP, VanderLaan PA, Zsengeller ZK, Pernicone E, Preston IR, Yu PB, Nikolic I, Xu D, Thadhani RI, Channick RN, Ananth Karumanchi S. Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension. Pulmonary circulation. 2016;6:498–507.CrossRefGoogle Scholar
  11. 11.
    Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol. 2013;59:367–74.CrossRefGoogle Scholar
  12. 12.
    Xiol X, Tremosa G, Castellote J, Gornals J, Lama C, Lopez C, Figueras J. Liver transplantation in patients with hepatic hydrothorax. Transplant Int: Off J Eur Soc Organ Transplant. 2005;18:672–5.CrossRefGoogle Scholar
  13. 13.
    Rybak D, Fallon MB, Krowka MJ, Brown RS Jr, Reinen J, Stadheim L, Faulk D, Nielsen C, Al-Naamani N, Roberts K, Zacks S, Perry T, Trotter J, Kawut SM. Pulmonary vascular complications of liver disease study G. Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. Liver Transplant: Off Publ Am Assoc Study Liver Diseases Inte Liver Transplant Soc. 2008;14:1357–65.CrossRefGoogle Scholar
  14. 14.
    Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.CrossRefGoogle Scholar
  15. 15.
    Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, Vargas HE, Douglas DD. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transplant: Off Publ Am Assoc Study Liver Diseases Inte Liver Transplant Soc. 2010;16:1373–8.CrossRefGoogle Scholar
  16. 16.
    Carey EJ, Iyer VN, Nelson DR, Nguyen JH, Krowka MJ. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency-related cirrhosis. Liver Transplant: Off Publ Am Assoc Study Liver Diseases Inte Liver Transplant Soc. 2013;19:1370–6.CrossRefGoogle Scholar
  17. 17.
    Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, Phillips JA 3rd, Lansdorp PM, Loyd JE, Armanios MY. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A. 2008;105:13051–6.CrossRefGoogle Scholar
  18. 18.
    Corso RM, Gregoretti C, Braghiroli A, Fanfulla F, Insalaco G. Practice guidelines for the perioperative Management of Patients with obstructive sleep apnea: navigating through uncertainty. Anesthesiology. 2014;121:664–5.CrossRefGoogle Scholar
  19. 19.
    Chung F, Abdullah HR, Liao P. STOP-Bang questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149:631–8.CrossRefGoogle Scholar
  20. 20.
    Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Riviere S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307:948–55.CrossRefGoogle Scholar
  21. 21.
    Trerotola SO, Pyeritz RE, White RI Jr, Picus D, Miller FJ, Foundation HHT, Centers HHT. 2009 treatment guidelines for hereditary hemorrhagic telangiectasia. J Vasc Interv Radiol. 2010;21:179.CrossRefGoogle Scholar
  22. 22.
    Lyle MA, Fenstad ER, McGoon MD, Frantz RP, Krowka MJ, Kane GC, Swanson KL. Pulmonary hypertension in hereditary hemorrhagic telangiectasia. Chest. 2016;149:362–71.CrossRefGoogle Scholar
  23. 23.
    Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2012;81:2417–22.CrossRefGoogle Scholar
  24. 24.
    Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med. 2008;358:2378–87.CrossRefGoogle Scholar
  25. 25.
    Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, Kim WR. MELD and PELD: application of survival models to liver allocation. Liver Transplant: Off Publ Am Assoc Study Liver Diseases Inte Liver Transplant Soc. 2001;7:567–80.CrossRefGoogle Scholar
  26. 26.
    Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122:164–72.CrossRefGoogle Scholar
  27. 27.
    Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology. 2014;59:1627–37.CrossRefGoogle Scholar
  28. 28.
    Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–65.CrossRefGoogle Scholar
  29. 29.
    Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, Troisi RI, Van Vlierberghe H, De Pauw M. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl. 2013;19:602–10.CrossRefGoogle Scholar
  30. 30.
    Netzer N, Eliasson AH, Netzer C, Kristo DA. Overnight pulse oximetry for sleep-disordered breathing in adults: a review. Chest. 2001;120:625–33.CrossRefGoogle Scholar
  31. 31.
    De BK, Dutta D, Pal SK, Gangopadhyay S, Das Baksi S, Pani A. The role of garlic in hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol. 2010;24:183–8.CrossRefGoogle Scholar
  32. 32.
    Fauconnet P, Klopfenstein CE, Schiffer E. Hepatopulmonary syndrome: the anaesthetic considerations. Eur J Anaesthesiol. 2013;30:721–30.CrossRefGoogle Scholar
  33. 33.
    Nayyar D, Man HS, Granton J, Lilly LB, Gupta S. Proposed management algorithm for severe hypoxemia after liver transplantation in the hepatopulmonary syndrome. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2015;15:903–13.CrossRefGoogle Scholar
  34. 34.
    Schenk P, Madl C, Rezaie-Majd S, Lehr S, Muller C. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med. 2000;133:701–6.CrossRefGoogle Scholar
  35. 35.
    Roma J, Balbi E, Pacheco-Moreira L, Gonzalez AC, Leal CG, Pousa F, Zynger I, Leite D, Halpern M, Guerra PP, Covelo M, Carius L, Agoglia L, Oliveira A, Enne M. Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report. Transplant Proc. 2010;42:601–4.CrossRefGoogle Scholar
  36. 36.
    Taille C, Cadranel J, Bellocq A, Thabut G, Soubrane O, Durand F, Ichai P, Duvoux C, Belghiti J, Calmus Y, Mal H. Liver transplantation for hepatopulmonary syndrome: a ten-year experience in Paris, France. Transplantation. 2003;75:1482–9. discussion 1446-1487CrossRefGoogle Scholar
  37. 37.
    DuBrock HM, Channick RN, Krowka MJ. What's new in the treatment of portopulmonary hypertension? Expert Rev Gastroenterol Hepatol. 2015;9:983–92.CrossRefGoogle Scholar
  38. 38.
    Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg. 1999;5:362–5.CrossRefGoogle Scholar
  39. 39.
    Faisal M, Siddiqi F, Alkaddour A, Bajwa AA, Shujaat A. Effect of PAH specific therapy on pulmonary hemodynamics and six-minute walk distance in portopulmonary hypertension: a systematic review and meta-analysis. Pulmonary medicine. 2014;2014:528783.CrossRefGoogle Scholar
  40. 40.
    Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transplant: Off Publ Am Assoc Study Liver Diseases Inte Liver Transplant Soc. 2000;6:443–50.CrossRefGoogle Scholar
  41. 41.
    DeMartino ES, Cartin-Ceba R, Findlay JY, Heimbach JK, Krowka MJ. Frequency and outcomes of patients with increased mean pulmonary artery pressure at the time of liver transplantation. Transplantation. 2017;101:101–6.CrossRefGoogle Scholar
  42. 42.
    Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–6.CrossRefGoogle Scholar
  43. 43.
    Fussner LA, Iyer VN, Cartin-Ceba R, Lin G, Watt KD, Krowka MJ. Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival. In: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the international liver transplantation society, vol. 21; 2015. p. 1355.Google Scholar
  44. 44.
    Murray KF, Carithers RL Jr. AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407–32.CrossRefGoogle Scholar
  45. 45.
    Ramsay M. Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol. 2010;23:145–50.CrossRefGoogle Scholar
  46. 46.
    Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: an update. Liver Transplant: Off Publ Am Assoc Study Liver Diseases Inte Liver Transplant Soc. 2012;18:881–91.CrossRefGoogle Scholar
  47. 47.
    Ramsay MA, Spikes C, East CA, Lynch K, Hein HA, Ramsay KJ, Klintmalm GB. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology. 1999;90:299–301.CrossRefGoogle Scholar
  48. 48.
    Stratta C, Lavezzo B, Ballaris MA, Panio A, Crucitti M, Andruetto P, Fanelli V, Grosso Marra W, Ranieri MV, Salizzoni M. Extracorporeal membrane oxygenation rescue therapy in a case of portopulmonary hypertension during liver transplantation: a case report. Transplant Proc. 2013;45:2774–5.CrossRefGoogle Scholar
  49. 49.
    Fukazawa K, Poliac LC, Pretto EA. Rapid assessment and safe management of severe pulmonary hypertension with milrinone during orthotopic liver transplantation. Clin Transpl. 2010;24:515–9.CrossRefGoogle Scholar
  50. 50.
    Goldberg DS, Krok K, Batra S, Trotter JF, Kawut SM, Fallon MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology. 2014;146:1256–65. e1251CrossRefGoogle Scholar
  51. 51.
    Iyer VN, Swanson KL, Cartin-Ceba R, Dierkhising RA, Rosen CB, Heimbach JK, Wiesner RH, Krowka MJ. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology. 2013;57:2427–35.CrossRefGoogle Scholar
  52. 52.
    Aucejo F, Miller C, Vogt D, Eghtesad B, Nakagawa S, Stoller JK. Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: a report of 2 cases and review of the literature. Liver Transplant: Off Publ Am Assoc Study Liver Diseases Inte Liver Transplant Soc. 2006;12:1278–82.CrossRefGoogle Scholar
  53. 53.
    Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8:2445–53.CrossRefGoogle Scholar
  54. 54.
    Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD. Portopulmonary hypertension: a report from the US-based REVEAL registry. Chest. 2012;141:906–15.CrossRefGoogle Scholar
  55. 55.
    Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, Elliot CA, Fisher AJ, Gaine S, Gibbs JSR, Gatzoulis MA, EH C, Howard LS, Johnson M, Kiely DG, Lordan JL, Peacock AJ, Pepke-Zaba J, Schreiber BE, Sheares KKK, Wort SJ, Corris PA. National Pulmonary Hypertension Service Research Collaboration of the united K, Ireland. Survival in portopulmonary hypertension: outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. J Heart Lung Transplant. 2017;36:770–9.CrossRefGoogle Scholar
  56. 56.
    Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, Jais X, Yaici A, Humbert M, Simonneau G, Sitbon O. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178:637–43.CrossRefGoogle Scholar
  57. 57.
    DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, Mulligan DC, Kremers WK, Kawut SM, Krowka MJ, Channick RN. Predictors of waitlist mortality in Portopulmonary hypertension. Transplantation. 2017;101:1609–15.CrossRefGoogle Scholar
  58. 58.
    Salgia RJ, Goodrich NP, Simpson H, Merion RM, Sharma P. Outcomes of liver transplantation for Porto-pulmonary hypertension in model for end-stage liver disease era. Dig Dis Sci. 2014;59:1976–82.CrossRefGoogle Scholar
  59. 59.
    Khaderi S, Khan R, Safdar Z, Stribling R, Vierling JM, Goss JA, Sussman NL. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl. 2014;20:724–7.CrossRefGoogle Scholar
  60. 60.
    Verma S, Hand F, Armstrong MJ, de Vos M, Thorburn D, Pan T, Klinck J, Westbrook RH, Auzinger G, Bathgate A, Masson S, Holt A, Houlihan DD, Ferguson JW. Portopulmonary hypertension: still an appropriate consideration for liver transplantation? Liver Transpl. 2016;22:1637–42.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations